论文部分内容阅读
本文报道应用抗CD3、CD4单抗及胸腺细胞球蛋白(AHTG)多抗治疗82例使用环孢素A(CsA)的急性移植肾排斥患者,其中单抗组(M组)52例;多抗组(P组)30例。难治性移植肾排斥M组46例,P组24例。结果单抗及多抗作为第一线抗排斥治疗各6例患者均完全逆转,难治性排斥逆转率:M组86.9%,P组66.7%。本文还对单抗及多抗治疗移植肾排斥过程中的多种因素作了分析讨论。
In this paper, 82 patients with acute renal transplant rejection using CsA were treated with anti-CD3, CD4 monoclonal antibody and multi-antibody against thymocyte globulin (AHTG), of which 52 were monoclonal antibody (M group) Group (P group) 30 cases. 46 cases of refractory transplant rejection in M group, 24 cases in P group. Results MAb and polyclonal anti-rejection treatment of the first line of six patients were completely reversed, refractory rejection rate: M group 86.9%, P group 66.7%. This article also analyzes and discusses many factors in the process of monoclonal antibody and multi-anti-rejection of renal allograft.